San Diego-based mostly Viking Therapeutics marked by itself as a significant competitor in the weight loss drug market place in February soon after revealing promising knowledge from the mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided to be a weekly injection and in M